CID seminar, Targeting CD40-CD154 interactions in transplantation and autoimmune diseases, 30 August

CID Weekly Seminar: Tuesday 30 August 2016, 12:00 - 1:00pm

Seminar Room 1, Level 2, TRF Building

Presented by Dr James Rush

Senior Investigator

Autoimmunity, Transplantation and Inflammation Diseases, Novartis Institutes for BioMedical Research (NIBR) 

Basel, Switzerland

Dr. James Rush is a Senior Investigator in the Autoimmunity, Transplantation and Inflammation disease area at the Novartis Institutes for BioMedical Research (NIBR) in Basel. His lab focuses on translational immunology research and the development of therapeutics targeting co-stimulation pathways dysregulated in autoimmunity. Areas of interest include utilizing ‘omics technologies to classify autoimmune diseases at the molecular level, translational research and human immunology. After completing a PhD in cellular immunology at the Centenary Institute with Dr. Phil Hodgkin, he was a HHMI postdoctoral researcher at Yale University in the laboratories of David Schatz and Charlie Janeway. Subsequently he joined the Genomics Institute of the Novartis Research Foundation in San Diego in May 2005 where his lab utilized high throughput genomics and small molecule screening technologies to identify novel regulators of innate immune receptor and B cell function. He then moved to NIBR Basel in 2008 to lead the development of a novel immunomodulatory drug for transplantation and antibody-mediated autoimmune diseases that is now undergoing clinical evaluation.

A light lunch is served prior to the seminar at 11:45am in the seminar room foyer, level 2, TRF Building.

Further information available from CID Weekly Seminar Series website [http://www.med.monash.edu.au/scs/medicine/cid/seminar-series.html]